Annual Cash & Cash Equivalents
$22.95 M
-$22.05 M-49.00%
31 December 2023
Summary:
Ligand Pharmaceuticals Incorporated annual cash & cash equivalents is currently $22.95 million, with the most recent change of -$22.05 million (-49.00%) on 31 December 2023. During the last 3 years, it has fallen by -$24.66 million (-51.80%). LGND annual cash & cash equivalents is now -85.67% below its all-time high of $160.20 million, reached on 31 December 2014.LGND Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$63.62 M
+$45.48 M+250.73%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated quarterly cash and cash equivalents is currently $63.62 million, with the most recent change of +$45.48 million (+250.73%) on 30 September 2024. Over the past year, it has increased by +$44.34 million (+230.06%). LGND quarterly cash and cash equivalents is now -86.08% below its all-time high of $456.92 million, reached on 30 September 2020.LGND Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LGND Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -49.0% | +230.1% |
| 3 y3 years | -51.8% | +171.5% |
| 5 y5 years | -80.4% | -71.8% |
LGND Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -51.8% | +17.6% | -28.3% | +1445.7% |
| 5 y | 5 years | -80.4% | +17.6% | -86.1% | +1445.7% |
| alltime | all time | -85.7% | +586.0% | -86.1% | +8988.4% |
Ligand Pharmaceuticals Incorporated Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $63.62 M(+250.7%) |
| June 2024 | - | $18.14 M(-63.8%) |
| Mar 2024 | - | $50.09 M(+118.2%) |
| Dec 2023 | $22.95 M(-49.0%) | $22.95 M(+19.1%) |
| Sept 2023 | - | $19.27 M(-32.2%) |
| June 2023 | - | $28.45 M(-67.9%) |
| Mar 2023 | - | $88.73 M(+97.1%) |
| Dec 2022 | $45.01 M(+130.5%) | $45.01 M(+993.4%) |
| Sept 2022 | - | $4.12 M(-22.0%) |
| June 2022 | - | $5.28 M(-64.8%) |
| Mar 2022 | - | $14.99 M(-23.2%) |
| Dec 2021 | $19.52 M(-59.0%) | $19.52 M(-16.7%) |
| Sept 2021 | - | $23.43 M(+7.2%) |
| June 2021 | - | $21.86 M(-31.4%) |
| Mar 2021 | - | $31.85 M(-33.1%) |
| Dec 2020 | $47.62 M(-33.4%) | $47.62 M(-89.6%) |
| Sept 2020 | - | $456.92 M(+296.8%) |
| June 2020 | - | $115.16 M(-2.0%) |
| Mar 2020 | - | $117.53 M(+64.3%) |
| Dec 2019 | $71.54 M(-38.9%) | $71.54 M(-68.2%) |
| Sept 2019 | - | $225.30 M(-17.5%) |
| June 2019 | - | $273.05 M(+159.8%) |
| Mar 2019 | - | $105.11 M(-10.3%) |
| Dec 2018 | $117.16 M(+468.2%) | $117.16 M(+1.4%) |
| Sept 2018 | - | $115.56 M(-23.7%) |
| June 2018 | - | $151.46 M(+196.8%) |
| Mar 2018 | - | $51.02 M(+147.4%) |
| Dec 2017 | $20.62 M(+10.0%) | $20.62 M(-37.0%) |
| Sept 2017 | - | $32.74 M(-45.6%) |
| June 2017 | - | $60.22 M(+466.0%) |
| Mar 2017 | - | $10.64 M(-43.3%) |
| Dec 2016 | $18.75 M(-80.8%) | $18.75 M(-78.3%) |
| Sept 2016 | - | $86.58 M(+41.1%) |
| June 2016 | - | $61.35 M(+96.1%) |
| Mar 2016 | - | $31.29 M(-67.9%) |
| Dec 2015 | $97.43 M(-39.2%) | $97.43 M(+3.9%) |
| Sept 2015 | - | $93.77 M(-13.4%) |
| June 2015 | - | $108.24 M(-34.7%) |
| Mar 2015 | - | $165.77 M(+3.5%) |
| Dec 2014 | $160.20 M(+1276.4%) | $160.20 M(-11.3%) |
| Sept 2014 | - | $180.66 M(+1142.8%) |
| June 2014 | - | $14.54 M(+12.0%) |
| Mar 2014 | - | $12.98 M(+11.5%) |
| Dec 2013 | $11.64 M(-6.0%) | $11.64 M(+255.8%) |
| Sept 2013 | - | $3.27 M(-44.8%) |
| June 2013 | - | $5.92 M(+17.6%) |
| Mar 2013 | - | $5.04 M(-59.3%) |
| Dec 2012 | $12.38 M(+75.8%) | $12.38 M(+75.7%) |
| Sept 2012 | - | $7.05 M(-20.7%) |
| June 2012 | - | $8.88 M(-9.1%) |
| Mar 2012 | - | $9.78 M(+38.9%) |
| Dec 2011 | $7.04 M(+110.4%) | $7.04 M(+212.8%) |
| Sept 2011 | - | $2.25 M(-34.6%) |
| June 2011 | - | $3.44 M(-43.0%) |
| Mar 2011 | - | $6.03 M(+80.3%) |
| Dec 2010 | $3.35 M(-79.1%) | $3.35 M(-11.9%) |
| Sept 2010 | - | $3.80 M(+17.3%) |
| June 2010 | - | $3.23 M(-20.0%) |
| Mar 2010 | - | $4.04 M(-74.8%) |
| Dec 2009 | $16.03 M | $16.03 M(+210.7%) |
| Sept 2009 | - | $5.16 M(+45.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2009 | - | $3.55 M(-27.9%) |
| Mar 2009 | - | $4.92 M(-82.9%) |
| Dec 2008 | $28.75 M(-62.6%) | $28.75 M(+143.6%) |
| Sept 2008 | - | $11.80 M(-59.6%) |
| June 2008 | - | $29.18 M(-51.0%) |
| Mar 2008 | - | $59.54 M(-22.5%) |
| Dec 2007 | $76.81 M(-51.5%) | $76.81 M(+10.8%) |
| Sept 2007 | - | $69.30 M(-33.1%) |
| June 2007 | - | $103.61 M(-74.3%) |
| Mar 2007 | - | $403.91 M(+155.0%) |
| Dec 2006 | $158.40 M(+137.3%) | $158.40 M(+1479.4%) |
| Sept 2006 | - | $10.03 M(-75.9%) |
| June 2006 | - | $41.62 M(-16.4%) |
| Mar 2006 | - | $49.81 M(-25.4%) |
| Dec 2005 | $66.76 M(-27.7%) | $66.76 M(+34.6%) |
| Sept 2005 | - | $49.59 M(+52.2%) |
| June 2005 | - | $32.58 M(-36.1%) |
| Mar 2005 | - | $50.96 M(-44.8%) |
| Dec 2004 | $92.31 M(+56.4%) | $92.31 M(+100.6%) |
| Sept 2004 | - | $46.02 M(+9.8%) |
| June 2004 | - | $41.92 M(-36.1%) |
| Mar 2004 | - | $65.56 M(+11.1%) |
| Dec 2003 | $59.03 M(+39.1%) | $59.03 M(-19.1%) |
| Sept 2003 | - | $73.00 M(+201.1%) |
| June 2003 | - | $24.25 M(+86.8%) |
| Mar 2003 | - | $12.98 M(-69.4%) |
| Dec 2002 | $42.42 M(+104.5%) | $42.42 M(+83.0%) |
| Sept 2002 | - | $23.18 M(-7.6%) |
| June 2002 | - | $25.09 M(+37.9%) |
| Mar 2002 | - | $18.19 M(-12.3%) |
| Dec 2001 | $20.74 M(+124.9%) | $20.74 M(+16.8%) |
| Sept 2001 | - | $17.75 M(-37.9%) |
| June 2001 | - | $28.60 M(+36.4%) |
| Mar 2001 | - | $20.97 M(+127.4%) |
| Dec 2000 | $9.22 M(-69.2%) | $9.22 M(-22.9%) |
| Sept 2000 | - | $11.97 M(-48.3%) |
| June 2000 | - | $23.16 M(-3.0%) |
| Mar 2000 | - | $23.88 M(-20.1%) |
| Dec 1999 | $29.90 M(-8.8%) | $29.90 M(+12.0%) |
| Sept 1999 | - | $26.70 M(+217.9%) |
| June 1999 | - | $8.40 M(-23.6%) |
| Mar 1999 | - | $11.00 M(-66.5%) |
| Dec 1998 | $32.80 M(-47.4%) | $32.80 M(+31.7%) |
| Sept 1998 | - | $24.90 M(-2.7%) |
| June 1998 | - | $25.60 M(-1.9%) |
| Mar 1998 | - | $26.10 M(-58.1%) |
| Dec 1997 | $62.30 M(+79.0%) | $62.30 M(+364.9%) |
| Sept 1997 | - | $13.40 M(-24.3%) |
| June 1997 | - | $17.70 M(-22.4%) |
| Mar 1997 | - | $22.80 M(-34.5%) |
| Dec 1996 | $34.80 M(+117.5%) | $34.80 M(+397.1%) |
| Sept 1996 | - | $7.00 M(-37.5%) |
| June 1996 | - | $11.20 M(-32.1%) |
| Mar 1996 | - | $16.50 M(+3.1%) |
| Dec 1995 | $16.00 M(+110.5%) | $16.00 M(+31.1%) |
| Sept 1995 | - | $12.20 M(-8.3%) |
| Mar 1995 | - | $13.30 M(+75.0%) |
| Dec 1994 | $7.60 M | $7.60 M(-37.2%) |
| Sept 1994 | - | $12.10 M(+1628.6%) |
| June 1994 | - | $700.00 K(-66.7%) |
| Mar 1994 | - | $2.10 M |
FAQ
- What is Ligand Pharmaceuticals Incorporated annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated annual cash & cash equivalents year-on-year change?
- What is Ligand Pharmaceuticals Incorporated quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated quarterly cash and cash equivalents year-on-year change?
What is Ligand Pharmaceuticals Incorporated annual cash & cash equivalents?
The current annual cash & cash equivalents of LGND is $22.95 M
What is the all time high annual cash & cash equivalents for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high annual cash & cash equivalents is $160.20 M
What is Ligand Pharmaceuticals Incorporated annual cash & cash equivalents year-on-year change?
Over the past year, LGND annual cash & cash equivalents has changed by -$22.05 M (-49.00%)
What is Ligand Pharmaceuticals Incorporated quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of LGND is $63.62 M
What is the all time high quarterly cash and cash equivalents for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high quarterly cash and cash equivalents is $456.92 M
What is Ligand Pharmaceuticals Incorporated quarterly cash and cash equivalents year-on-year change?
Over the past year, LGND quarterly cash and cash equivalents has changed by +$44.34 M (+230.06%)